Program
Fulvestrant
Also written as “PF-07104091 + PF-07220060 + fulvestrant dose expansion”, “fulvestrant” and “faslodex 500mg”.
Its studies are mostly in Breast Neoplasms · Neoplasms · Carcinoma, Intraductal, Noninfiltrating · Puberty, Precocious · Endometrial Neoplasms, led by 5 companies.
Drug pageFulvestrant: every studyMany companies study it; this page follows only the 25 they lead. All 122 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 211 open or running | phase 4since May 4, 2015 | Jul 21, 2003 | none ahead |
| Atossa Therapeuticsits history only | 10 open or running | phase 2since Aug 28, 2015 | Aug 28, 2015 | none ahead |
| Criteriumits history only | 11 open or running | phase 2since Sep 3, 2020 | Sep 3, 2020 | Dec 31, 2027phase 2 · NCT04567420 |
| Eagle Pharmaceuticalsits history only | 10 open or running | phase 1since Oct 24, 2017 | Oct 24, 2017 | none ahead |
| Fresenius Kabiits history only | 10 open or running | phase 1since May 30, 2016 | May 30, 2016 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 11 studies since Jul 21, 2003.
- Apr 10, 2006Phase 2 study in Breast NeoplasmsAstraZeneca · NCT00313170 · 144 enrolled · Belgium, Canada, Czechia and more
- May 18, 2006Phase 1 study in Advanced Breast CancerAstraZeneca · NCT00328120 · 20 enrolled · Japan
- May 18, 2006Phase 3 study in Advanced Breast CancerAstraZeneca · NCT00327769 · 234 enrolled · China
- Jun 5, 2006Phase 2 study in Endometrial NeoplasmsAstraZeneca · NCT00334295 · 35 enrolled · Germany
- Jul 20, 2006Phase 2 study in Breast NeoplasmsAstraZeneca · NCT00357110 · 13 enrolled · Austria, Germany, Norway
- Mar 7, 2008Phase 3 study in Advanced Breast CancerAstraZeneca · NCT00635713 · 588 enrolled
- Jul 22, 2009Phase 3 study in Breast NeoplasmsAstraZeneca · NCT00944918 · 25 enrolled · Korea, Republic of
- Feb 17, 2011Phase 3 study in Breast NeoplasmsAstraZeneca · NCT01300351 · 249 enrolled · China
- May 11, 2012Phase 3 study in NeoplasmsAstraZeneca · NCT01602380 · 462 enrolled · United States, Argentina, Brazil and more
- May 4, 2015Phase 4 study in Breast NeoplasmsAstraZeneca · NCT02447328 · 83 enrolled · Korea, Republic of
- Aug 28, 2015Atossa Therapeutics’ first study: phase 2 study in Female Breast CarcinomaNew to Atossa TherapeuticsAtossa Therapeutics · NCT02540330 · 3 enrolled · United States
- May 30, 2016Fresenius Kabi’s first study: phase 1 study in HealthyNew to Fresenius KabiFresenius Kabi · NCT02795039 · 266 enrolled · Canada
- Oct 24, 2017Eagle Pharmaceuticals’ first study: phase 1 study in PharmacokineticsNew to Eagle PharmaceuticalsEagle Pharmaceuticals · NCT03324061 · 600 enrolled · United States
- Sep 3, 2020Criterium’s first study: phase 2 study in Breast NeoplasmsNew to CriteriumCriterium · NCT04567420 · 70 enrolled · United States
Ahead
- Dec 31, 2027Primary completion: phase 2 study in Breast NeoplasmsCriterium · NCT04567420
TargetBeta
“Estrogen receptor alpha antagonist; Estrogen receptor degrader”ChEMBL 37, by rule
Other programs on ESR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Ethinyl Estradiolrule | Johnson & Johnson | phase 4 | 70 |
| Estradiolrule | Novo Nordisk | phase 4 | 69 |
| Tamoxifenrule | AstraZeneca | phase 4 | 21 |
| Clomiphenerule | Hamad Medical | phase 4 | 3 |
| vepdegestrantrule | Pfizer | phase 3 | 20 |
| camizestrantrule | AstraZeneca | phase 3 | 18 |
| giredestrant | Hoffmann-La Roche | phase 3 | 17 |
| HRS-8080 | Jiangsu HengRui Medicine | phase 3 | 13 |
| elacestrantrule | Menarini Group | phase 3 | 12 |
| Imlunestrantrule | Eli Lilly | phase 3 | 12 |
| taragarestrantrule | InventisBio | phase 3 | 5 |
| SIM0270rule | Simcere Pharmaceutical Group | phase 3 | 5 |
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT04567420Breast Neoplasms · United States | 2 | Active, not recruiting | Criterium | Dec 31, 2027 | 70 |
| NCT03324061Pharmacokinetics · United States | 1 | Completed | Eagle Pharmaceuticals | Jul 12, 2018 | 600 |
| NCT02795039Healthy · Canada | 1 | Completed | Fresenius Kabi | Mar 3, 2017 | 266 |
| NCT02540330Female Breast Carcinoma · United States | 2 | Terminated | Atossa Therapeutics | Aug 13, 2020 | 3 |
| NCT02447328Breast Neoplasms · Korea, Republic of | 4 | Completed | AstraZeneca | May 6, 2016 | 83 |
| NCT01602380Neoplasms · United States, Argentina, Brazil and more | 3 | Completed | AstraZeneca | Apr 11, 2016 | 462 |
| NCT01300351Breast Neoplasms · China | 3 | Completed | AstraZeneca | Mar 2014 | 249 |
| NCT00944918Breast Neoplasms · Korea, Republic of | 3 | Completed | AstraZeneca | Jun 2011 | 25 |
| NCT00635713Advanced Breast Cancer | 3 | Completed | AstraZeneca | 588 | |
| NCT00357110Breast Neoplasms · Austria, Germany, Norway | 2 | Completed | AstraZeneca | Oct 2008 | 13 |
| NCT00334295Endometrial Neoplasms · Germany | 2 | Completed | AstraZeneca | Jan 2011 | 35 |
| NCT00328120Advanced Breast Cancer · Japan | 1 | Completed | AstraZeneca | Apr 2006 | 20 |
| NCT00327769Advanced Breast Cancer · China | 3 | Completed | AstraZeneca | 234 | |
| NCT00313170Breast Neoplasms · Belgium, Canada, Czechia and more | 2 | Completed | AstraZeneca | Jun 13, 2008 | 144 |
| NCT00305448Breast Neoplasms · Japan | 2 | Completed | AstraZeneca | Mar 2008 | 143 |
| NCT00278915Puberty, Precocious · United States, France, Germany and more | 2 | Completed | AstraZeneca | Dec 8, 2009 | 30 |
| NCT00274469Breast Neoplasms · United States, Brazil, Bulgaria and more | 2 | Completed | AstraZeneca | Jan 10, 2008 | 205 |
| NCT00272740Breast Neoplasms · Belgium, Switzerland | 2 | Completed | AstraZeneca | 93 | |
| NCT00259090Breast Neoplasms · United Kingdom | 2 | Completed | AstraZeneca | Oct 2008 | 120 |
| NCT00256698Breast Neoplasms · Canada, Costa Rica, Finland and more | 3 | Completed | AstraZeneca | Apr 2009 | 514 |
| NCT00241449Breast Neoplasms · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | Mar 2007 | 51 |
| NCT00234403Breast Neoplasms · Spain | 2 | Completed | AstraZeneca | 60 | |
| NCT00099437Breast Neoplasms · United States, Belgium, Brazil and more | 3 | Active, not recruiting | AstraZeneca | Feb 27, 2009 | 736 |
| NCT00093002Breast Neoplasms · United States, Austria, Brazil and more | 2 | Completed | AstraZeneca | 179 | |
| NCT00065325Breast Neoplasms · United States, Argentina, Belgium and more | 3 | Completed | AstraZeneca | Jun 2006 | 694 |
How it is read
Names in the registry
- “Fulvestrant”, 26 entries
- “PF-07104091 + PF-07220060 + fulvestrant dose expansion”, 2 entries
- “fulvestrant”, 2 entries
- “faslodex 500mg”, 1 entry
- “Fulvestrant injection”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 23 studies
- Neoplasms, 1 study
- Carcinoma, Intraductal, Noninfiltrating, 1 study
- Puberty, Precocious, 1 study
- Endometrial Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.